(This isn't a requirement for other drugs that plans cover, but obesity has consistently brought up the ROI discussion) --- Of course, your plan will vary depending on the population and implementation, but how are benefits teams thinking about that ~$10 PMPM right now
This project highlights our ongoing commitment to furthering their development and manufacturing." Joerg Ahlgrimm, CEO of SK pharmteco Read the full story here: #Biopharma #CDMO #PharmaceuticalManufacturing #DrugDevelopment To view or add a comment, sign in Elemental Impurities in Pharmaceutical Products Elemental impurities such as arsenic, lead, cadmium, mercury, and others may enter drug formulations from raw materials, catalysts, or equipment
Dysaesthesia, an unpleasant and often painful sensation, such as burning or tingling under the skin, was also more common in the 7.2 mg group (22.9% vs 6.0%)
GLP-1 receptor agonists and diabetic retinopathy